M
Myome
Biotech & Life Sciences · Menlo Park, United States · Founded 2017
Helps identify genes that cause disease and act based on leading science MoreLess
MyOme is a biotechnology company specializing in clinical-grade whole genome sequencing to provide a comprehensive picture of disease risk. The company serves families and individuals looking to understand their genetic predispositions to both common and rare diseases. Operating in the genomics and personalized medicine market, MyOme combines advanced machine learning and AI technologies to generate integrated disease risk scores that evolve with lifestyle changes. The business model revolves around offering a single, detailed genetic test that delivers actionable insights over a lifetime, thereby enabling earlier health interventions and better disease management. Revenue is generated through the sale of these genetic tests and associated health insights.
Keywords: genomics, personalized medicine, disease risk, whole genome sequencing, AI, machine learning, health intervention, genetic predispositions, clinical-grade, actionable insights.
Company overview
Myome company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Menlo Park, United States
- Employees
- 91
- Open positions
- 9
- Dealroom signal
- 90.3
Valuation & funding
Myome funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2022 | $23M | $92M | Founders Fund · Natera · Healthcare Venture Partners · Sequoia | ↗ |
| SERIES BEquity / VC | Dec 2021 | $0 | — | Norwest Venture Partners | — |
| OtherOther financing | Oct 2019 | $0 | — | Norwest Venture Partners · HOF Capital | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 97 |
| 2025 | 71 |
| 2024 | 46 |
| 2023 | 28 |
| 2022 | 27 |
| 2021 | 14 |
Growth signals
Myome website traffic
Latest recorded traffic for Myome is 16K monthly website visits, up 33.3% over the last three months. Myome's team grew 28.2% over the past year.
Hiring
Open positions at Myome
Current openings linked to this company in Dealroom.
Comparisons
Myome compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Myome's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Myome has talent and traffic
team presence
In the news
Latest news about Myome
Recent press, funding announcements, and product moves mentioning Myome — open to read from the original sources.
Market sentiment
What the market is saying about Myome
An AI-synthesized read of the highest-engagement posts about Myome on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Myome’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.